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TO THE EDITOR
IL-33 is a newly discovered member of
the IL-1 family and is constitutively
expressed in the epithelial and endo-
thelial cells of various organs (Moussion
et al., 2008). IL-33 is important to the
T helper 2 (Th2) immune reaction
because its receptor, ST2L, is ex-
pressed on Th2 lymphocytes, baso-
phils, eosinophils, and mast cells
(Schmitz et al., 2005). It may also
function independently of the immune
reaction (Sanada et al., 2007). IL-33 is
usually found in the nucleus, produced
as pro-form IL-33 (pro-IL-33), and is
digested into a mature form with a
lower molecular weight when it is
secreted from the cells. Mature IL-33
was first thought to be the active form
(Schmitz et al., 2005). However, recent
reports have shown that the active
pro-form of IL-33 is digested into an
inactive mature form (Cayrol and
Girard, 2009).
Neonatal foreskin normal human
epidermal keratinocytes (NHEKs) were
purchased from Kurabo (Osaka, Japan)
and cultured in keratinocyte serum-free
medium (Invitrogen, Carlsbad, CA)
supplemented with bovine pituitary
extract (Kyokuto Seiyaku, Tokyo, Japan)
and epidermal growth factor (R&D
Systems, Minneapolis, MN). HaCaT
keratinocytes were a generous gift from
Dr Kuroki (Showa University) with the
permission of Dr Fusenig (Institute Fur
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Figure 1. Cells expressing full-length IL-33 messenger RNA (mRNA) at diverse levels. (a–c) Total RNA (1 mg) was reverse transcribed with a SuperScript III
Reverse Transcriptase Kit (Invitrogen). PCR was carried out for 35 cycles of 95 1C (20 s), 56 1C (20 s), and 72 1C (15 s), by TaKaRa Ex Taq polymerase (TaKaRa)
using ex1 (50-AGCCTTGTGTTTCAAGCTGG-30) and R1 (50-ATGGAGCTCCACAGAGTGTTC-30) primers. Products were visualized by electrophoresis on 1.5%
agarose gels stained with ethidium bromide. Arrowheads indicate products shorter than full-length IL-33. (d) Real-time PCR performed using the TaqMan
Real-time PCR System (ABI). The primers and probes for IL-33 and glyceraldehyde-3-phosphate dehydrogenase (GAPDH) were obtained from ABI. Quantities of
mRNA were measured relative to GAPDH mRNA levels. ND, not detected. Each bar denotes three independent experiments (mean±SD). (e) Nuclear (n) and
cytoplasmic (c) fractions of normal human epidermal keratinocytes were extracted using the Nuclear/Cytosol Fraction Kit (BioVision, Mountain View, CA).
Cell extracts were separated by SDS-PAGE and transferred onto polyvinylidene difluoride membrane. IL-33 was detected with anti-human IL-33 antibody
(NT; ProSci, Poway, CA).
Abbreviations: DFSP, dermatofibrosarcoma protuberans; FCS, fetal calf serum; HUVEC, human umbilical
vein endothelial cell; NHDF, normal human dermal fibroblast; NHEK, normal human epidermal
keratinocyte; Pen/St, penicillin/streptomycin; Th, T helper
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Figure 2. Genome organization, sequence, and expression of IL-33 splice variants in different types of cells. (a) Schematic diagram of splicing variant
structures. Exon 1 was not validated in this study (dashed box and line). (b) Multiple alignment of putative amino-acid sequences. Gray box: binding site to
histones H2 and H3; gradient box: putative nuclear-localization signal sequence. (c) PCR using primers designed to detect each splicing variant. a: Exon 3
deletion (50-CAAGCTGGGAAGTAGAAAGCAC-30), 410 bp; b: deletion of exons 3 and 4 (50-CAAGCTGGGAAGAATTTCACC-30), 280 bp; c: deletion of exons 3,
4, and 5 (50-CAAGCTGGGAAATAAGGTGTTAC-30), 150 bp; d: exon 4 deletion (50-CTGAAAACAGGAATTTCACC-30), 280 bp; e; deletion of exons 4 and 5
(50-CTGAAAACAGATAAGGTGTTACTG-30), 150 bp; f: exon 5 deletion (50-AGTATCACAGATAAGGTGTTACTG-30), 150 bp. PCR products were loaded into
a 1.5% agarose gel and visualized by ethidium bromide staining. (d) PCR analysis summary. þ þ : High expression; þ : moderate expression; : no expression.
(e) Expression patterns of recombinant IL-33 splice variants. Full-length IL-33 and some IL-33 splice variants were constructed using PCR. Two micrograms of
plasmid was transfected into 1 106 cells with FuGENE HD Transfection reagent (Promega). Nuclear (n) and cytoplasmic (c) fractions were extracted, and
recombinant proteins were detected with anti-FLAG antibody (Sigma, Saint Louis, Missouri). DFSP, dermatofibrosarcoma protuberans; HUVEC, human
umbilical vein endothelial cell; NHDF, normal human dermal fibroblasts; NHEK, normal human epidermal keratinocyte.
2662 Journal of Investigative Dermatology (2012), Volume 132
H Tsuda et al.
Novel Splice Variants of IL-33
Zell- und Tumourbiologie, Deutsches
Kresforschungszentrum, Heidelberg,
Germany). They were grown routinely
in Eagle’s minimum essential medium
(Invitrogen) supplemented with 10%
fetal calf serum (FCS) in a humidified
CO2 incubator. We used cells from the
30th to 50th passage. A human squa-
mous cell carcinoma cell line (DJM
cells) was established in the Depart-
ment of Dermatology, Jichi Medical
University (Katayama et al., 1991) and
cultured in DMEM (Invitrogen) with
10% FCS and 1% penicillin/streptomy-
cin (Pen/St). THP-1 cells were pur-
chased from the ATCC and cultured in
RPMI 1640 (Invitrogen) with 10% FCS
and 1% Pen/St.
Normal human dermal fibroblasts
(NHDF) were purchased from Kurabo.
Fibroblasts from dermatofibrosarcoma
protuberans (DFSP) were obtained from
tumors excised from patients after
informed consent was provided. The
human melanoma cell lines MM-AN,
MM-BP, MM-LH, MM-RU, and RPM-
MC were kindly provided by Dr H
Randolph Byers (Harvard Medical
School). All cell lines were established
from metastatic lymph nodes, except
for RPM-MC, which originated in a
recurrent primary lesion (Byers et al.,
1991). HEK293, A549, and HeLa cells
were cultured in DMEM with 10% FCS
containing 1% Pen/St.
Dr Yanagisawa (Jichi Medical Uni-
versity) kindly provided RNA extracted
from human umbilical vein endothelial
cells (HUVEC). The primers used in this
study were designed on the basis of the
full-length IL-33 sequence (GenBank
accession no. NM_033439, Baekke-
vold et al., 2003).
PCR products were extracted from
agarose gel using the Wizard SV Gel
and PCR Clean-Up System (Promega,
Tokyo, Japan). Purified fragments were
cloned into the EcoRV site of pBlue-
script SK(), and sequencing analysis
was performed with an ABI 310 Se-
quencer (Applied Biosystems, ABI, Nor-
walk, CT) using universal primers.
We attempted to evaluate the mes-
senger RNA expression levels of full-
length pro-IL-33 among multiple cell
types (Figure 1a–d). NHEKs, DFSP,
A549, and HUVEC expressed compar-
able levels of IL-33, whereas DJM,
HaCaT, and HEK293 expressed IL-33
at much lower levels. IL-33 was not
detected in HeLa cells. Several malig-
nant melanoma cell lines expressed
different levels of IL-33. NHEKs ex-
pressed higher levels of IL-33 than its
transformed variants did; however,
NHDF expressed lower levels of IL-33
than its transformed variant (DFSP cells)
did, suggesting that malignant transfor-
mation did not drive IL-33 expression
levels in a certain direction.
We suspected the existence of smal-
ler splice variants in the IL-33 PCR
products, because we observed several
smaller bands (Figure 1a–c). Using
western blotting, we also detected
several IL-33 bands in both nuclear
and cytoplasmic fractions (Figure 1e)
that were absent in IL-33 knockdown
cells (data not shown). We thus purified
a single PCR product from each of
the smaller bands and determined
the respective nucleotide sequences.
Sequencing revealed multiple IL-33
splice variants of different sizes, as shown
in Figure 2a. These include variants that
lack a single exon (3, 4, or 5), as well as
variants that simultaneously lack exons 3
and 4; 4 and 5; or 3, 4, and 5.
The amino-acid sequence of each
exon did not differ, except for variants
in which the deletion began at exon 3
(Figure 2b). The first amino acid follow-
ing the abnormal splicing event was
replaced by a different amino acid in
these variants because the splicing
event occurred within the first codon
of exon 3. The sequence of subsequent
amino acids was unchanged. Exons in
other splice variants were omitted in
their entirety.
We investigated whether these var-
iants are expressed in other cell types.
Figures 2c and d show that all exam-
ined cells expressed these splice vari-
ants, but in different proportions.
When expression vectors of these
splice variants were transfected into
NHEKs, full-length transcript as well
as D4 and D4–5, which are variants
lacking exon 4 and/or exon 5, were
detected in the nuclear fraction,
whereas D3, the construct lacking exon
3, was detected in the cytoplasmic
fraction (Figure 2e).
This study demonstrated the exis-
tence of multiple splice variants of
IL-33 in several different cell types,
with differing expression patterns
among different cell types.
The existence of multiple splice
variants is known for several cytokines,
including IL-2, IL-4, IL-6, IL-7, IL-10, IL-
21, and IL-24 (Whitaker et al., 2011). In
many of these cases, the protein pro-
ducts of alternatively spliced variants
function to modulate the activity of the
primary isoform.
A recent study demonstrated the
existence of an IL-33 splice variant
lacking exon 3 (exon 4 in this study),
and showed that the protein possesses
constitutive cytokine activity (Hong
et al., 2011).
Exon 3 contains a nuclear-localiza-
tion motif (Carriere et al., 2007), con-
sistent with the observation that
recombinant IL-33 that lacks this region
was not detected in the nucleus. There
was a tendency for the transformed cells
to lack certain splice variants, such as
those lacking exon 3 or 4, which
suggests that the transformation of
the cells may affect the pattern of
expression. This aspect requires further
study.
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TO THE EDITOR
One major risk factor for cutaneous
melanoma is UV exposure. Intense
intermittent UV exposure and child-
hood sunburn are linked epidemiologi-
cally with melanoma risk, and in mice
neonatal UV exposure promotes devel-
opment of cutaneous melanoma (Noo-
nan et al., 2001; Kannan et al., 2003).
Other evidence that UV contributes to
melanomagenesis includes increased
risk for populations with extensive
intense sun exposure, as well as for
fair-skinned (Fitzpatrick’s skin type I–II)
individuals and patients with xeroder-
ma pigmentosum, who repair photo-
products very poorly (Kraemer et al.,
1987; Gilchrest et al., 1999).
We have previously shown that
telomere homolog oligonucleotides
(collectively called T-oligos), but not
complementary or unrelated control
oligonucleotides, have multiple anti-
cancer effects (Eller et al., 1997; Puri
et al., 2004; Gilchrest and Eller, 2009).
T-oligo treatment before UV irradiation
accelerates the removal of major
UV-induced cyclobutane pyrimidine
dimers (CPDs) and 6-4 photoproducts
in cultured cells from newborn and
adult donors (Goukassian et al., 2002),
murine skin in vivo (Goukassian et al.,
2004; Arad et al., 2008), and human
skin ex vivo (Arad et al., 2007). T-oligos
have also been shown to cause cell
cycle arrest, followed in many malignant
cell types by apoptosis (Puri et al., 2004;
Gilchrest and Eller, 2009). We have
previously shown that treatment with T-
oligos (specifically, thymidine dinucleo-
tide (pTT)) during chronic UV irradiation
prevents development of squamous cell
carcinoma (SCC) in hairless mice (Gou-
kassian et al., 2004) and of basal cell
carcinoma (BCC) in Ptch-1þ / mice
(Arad et al., 2008). In these models,
intermittent topical pTT application
enhances DNA repair of CPDs and
8-oxo-20-deoxyguanosine and decreases
mutagenesis, and in tumor nodules it
increases apoptosis and decreases pro-
liferation. pTT also strikingly reduces
Cox-2 protein expression in UV-irra-
diated skin (Arad et al., 2008).
Many mutations associated with fami-
lial melanoma occur at the CDKN2A
locus that encodes two distinct proteins,
p16 INK4a and p14 ARF (p19 ARF in
mice) (Chudnovsky et al., 2005). Several
knockout (KO) and transgenic animal
models have been developed to study
p16- and p19-dependent molecular me-
chanisms of melanoma development. Of
interest to modeling human melanoma-
genesis, when p19ARF/mice expressing
H-ras driven by a tyrosinase promoter
(Tyr-Hras/p19KO mice) are UV irradiated
on day 2 or 3 after birth, there is a
significant increase in melanoma devel-
opment during early adulthood (Kannan
et al., 2003). In this study we evaluated
the effect of topical pTT treatment in this
model.
Newborn mice were treated topi-
cally with a 100 mM solution of pTT
(Midland Certified Reagent Company,
Midland, TX) or the PG/DMSO (propy-
lene glycol 75%/DMSO 25%) vehicle
alone on days 1 and 2, then UV
irradiated on day 3 using FS40 sun-
lamps (10mJ cm2) as metered at
285±5mm, an irradiation protocol
known to cause melanomas by week
21 in approximately half the mice
(Kannan et al., 2003).
pTT-treated mice began to develop
melanomas during week 12, whereas
vehicle-treated mice began to develop
tumors during week 7; and by week 21,
71% versus 46% of the mice remained
tumor free (Figure 1a). All mice were
examined weekly and killed if their
tumors were X1cm in diameter or the
Abbreviations: ANOVA, analysis of variance; BCC, basal cell carcinoma; CPD, cyclobutane pyramidine
dimer; KO, knockout; pTT, thymidine dinucleotide; PG/DMSO, propylene glycol 75%/DMSO 25%; SCC,
squamous cell carcinoma; T-oligo, telomere homolog oligonucleotide
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